JBC PeproTech; Our Business is Cytokines!

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M909882199 on March 15, 2000
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
275/19/14440    most recent
M909882199v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pack-Chung, E.
Right arrow Articles by Kim, T.-W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pack-Chung, E.
Right arrow Articles by Kim, T.-W.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 275, Issue 19, 14440-14445, May 12, 2000


Presenilin 2 Interacts with Sorcin, a Modulator of the Ryanodine Receptor*

Eunju Pack-ChungDagger , Marian B. Meyers§, Warren P. PettingellDagger , Robert D. MoirDagger , Amy M. Brownawell||, Isaac ChengDagger **, Rudolph E. TanziDagger , and Tae-Wan KimDagger Dagger Dagger

From the Dagger  Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, the § Department of Medicine, Cardiovascular Institute, Mount Sinai School of Medicine, New York, New York 10029, and the || Department of Pharmacology, University of Virginia, Charlottesville, Virginia 22908

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Perturbed Ca2+ homeostasis is a common molecular consequence of familial Alzheimer's disease-linked presenilin mutations. We report here the molecular interaction of the large hydrophilic loop region of presenilin 2 (PS2) with sorcin, a penta-EF-hand Ca2+-binding protein that serves as a modulator of the ryanodine receptor intracellular Ca2+ channel. The association of endogenous sorcin and PS2 was demonstrated in cultured cells and human brain tissues. Membrane-associated sorcin and a subset of the functional PS2 complexes were co-localized to a novel subcellular fraction that is distinctively positive for calcineurin B. Sorcin was found to interact with PS2 endoproteolytic fragments but not full-length PS2, and the sorcin/PS2 interaction was greatly enhanced by treatment with the Ca2+ ionophore A23187. Our findings reveal a molecular link between PS2 and intracellular Ca2+ channels (i.e. ryanodine receptor) and substantiate normal and/or pathological roles of PS2 in intracellular Ca2+ homeostasis.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Nearly half of early-onset familial Alzheimer's disease (FAD)1 is associated with mutations in genes encoding two homologous proteins, presenilin 1 (PS1) and presenilin 2 (PS2) (1). Recent studies have shown that PS1 (and perhaps PS2) plays an essential role in the gamma -secretase cleavage of amyloid beta -protein precursor (2-4) and the trafficking/maturation of other select cellular proteins, including Notch and TrkB (5-8). Common molecular consequences of presenilin FAD mutations include the increased production of amyloid beta -peptide x-42 and increased apoptosis (reviewed in Refs. 9-11). In addition, FAD mutations in both PS1 and PS2 have been shown to disrupt intracellular Ca2+ homeostasis (12, 13). However, the mechanism by which Ca2+ dyshomeostasis contributes to FAD pathogenesis is still unresolved.

Recently, a number of molecules that form complexes with the presenilins have been identified, including beta - and delta -catenin (14-19), p0071 (20), amyloid beta -protein precursor (21), filamin/Fh-1 (22), Notch (23), GSK3beta (24), Rab11 (25), calsenilin (26), calmyrin (27), QM/Jif-1 (28), and Bcl-XL (29). It is currently unclear whether these interactions mediate pathogenesis in presenilin FAD. It is also noteworthy that some of these proteins have been shown to interact either preferentially or exclusively with full-length presenilin over the N- or C-terminal fragments. Since only a subset of presenilin proteins are cleaved to form stable, functional presenilin complexes (30-35), and the remaining full-length proteins are degraded by the proteasome (32, 36-38), proteins that interact with the N- and/or C-terminal presenilin fragments are more likely to mediate presenilin function as opposed to maturation of the presenilins. Additionally, many of these presenilin-interacting proteins have been identified and characterized using overexpression in cell systems, whereas only a few have been demonstrated to interact with PS1 and/or PS2 endogenously (e.g. beta -catenin).

Although the N-terminal and loop domains are not conserved between the presenilins, FAD mutations have been identified within these regions in both proteins (1). We have identified the protein sorcin as a PS2 loop-interacting molecule. Sorcin is a penta-EF-hand Ca2+-binding protein that modulates the ryanodine receptor (RyR) intracellular calcium channel (39-43) and has previously been shown to be co-localize with brain RyR in the rat caudate-putamen nucleus (44). We have found that sorcin interacts with the stable C-terminal endoproteolytic fragment of PS2 but not with the immature full-length form. This interaction between sorcin and a subset of the functional PS2 complexes was modulated by Ca2+ and occurred in a novel subcellular fraction. Our results reveal a molecular link between PS2 and intracellular Ca2+ channels, suggesting that sorcin is involved in the role of PS2 in intracellular Ca2+ homeostasis.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Expression Constructs-- Molecular cloning of cDNAs encoding sorcin (40) and grancalcin (45) from an adult human brain cDNA library was performed using a Marathon-ready rapid amplification of cDNA ends kit (CLONTECH). Isolated full-length cDNAs were subcloned into the pcDNA3.1/myc-His mammalian expression vector (Invitrogen), and the inserts were sequenced using a double-stranded DNA cycle sequencing system (Life Technologies, Inc.). Inducible expression constructs (pUHD10-3) coding for wild-type and N141I mutant versions of PS2 were previously described (32). For the constitutive expression of PS2, the inserts from the inducible expression constructs (without FLAG epitope tags) were subcloned into pcDNA3.1/Zeo(+) (Invitrogen) and were fully verified by sequencing.

Generation of Stable PS2 Cell Lines-- Stable PS2 cell lines were generated by transfecting SH-SY5Y cells in a 100-mm dish with 5 µg of each plasmid: wild-type PS2, N141I PS2, or vector alone (pcDNA3.1/Zeo+). Individual zeocin-resistant colonies were isolated and screened for PS2 expression by Western blotting using alpha PS2Loop (30) and alpha G2L (46). Stable cell lines were maintained in the presence of 250 µg/ml Zeocin (Invitrogen) as described previously (32).

Antibodies, Western Blot Analyses, and Immunoprecipitation-- Protein quantitation, SDS-polyacrylamide gel electrophoresis (4-20 or 16%), and Western blotting were carried out as described previously (4, 56). Primary antibodies were used at the following dilutions: alpha PS2Loop (30) at 1:2500; alpha PS1Loop (30) at 1:3000; monoclonal anti-sorcin (39) at 1:2000; and polyclonal anti-sorcin (47) at 1:10,000. To quantitate relative amounts of presenilin and sorcin in the blots, Fluor-S MultiImager and MultiAnalyst software (Bio-Rad) were utilized. Cells or tissues were lysed using IP buffer (10 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Triton X-100, 0.25% Nonidet P-40, 2 mM EDTA) plus protease inhibitors, and solubilized proteins were subjected to immunoprecipitation. For the co-immunoprecipitation experiments, 0.25-0.5% Nonidet P-40 was utilized, and 0.1% bovine serum albumin was included. The samples were pre-cleared with protein A conjugated with magnetic beads (PerSeptive Diagnostics) for 1 h at 4 °C, incubated with antibodies overnight, further incubated with protein A-magnetic beads (30 µl/sample) for 2 h at 4 °C, and washed three times with IP buffer. Immunoprecipitates were collected using a magnetic bead collector, heated to 60 °C in sample buffer, and subjected to SDS-polyacrylamide gel electrophoresis and Western blotting. Antibodies used include GM130 (Transduction Laboratories), calnexin (Stressgene), transferrin receptor (a gift of Dr. I. Trowbridge), APS26 (15) (a gift of Anke Diehlmann and Konrad Beyreuther), and calcineurin B (Santa Cruz Biotechnology).

Confocal Microscopy-- Cells grown on glass coverslips or chamber slides were fixed (4% paraformaldehyde), double-stained with monoclonal anti-sorcin antibody and alpha PS2loop, and then incubated with Cy3-conjugated anti-mouse secondary antibodies (Jackson Laboratories) and Bodipy-conjugated anti-rabbit secondary antibodies (Molecular Probes). Fluorescent images were captured and analyzed using a Bio-Rad 1024 confocal microscope mounted on a Nikon inverted microscope.

Subcellular Fractionation-- Subcellular fractionation of cultured cells was performed using a protocol that has been previously described with minor modifications (48, 49). Cells were washed twice each with ice-cold phosphate-buffered saline and homogenization buffer (10 mM triethanolamine, 10 mM acetic acid, 250 mM sucrose, 1 mM EDTA, and 1 mM dithiothreitol) plus protease inhibitor mixture (Roche Molecular Biochemicals) and homogenized using a 25-gauge needle and a tight-pestle metal Dounce homogenizer. A post-nuclear supernatant resulting from low speed centrifugation was separated by differential centrifugation at 1,000 × g, 14,000 × g, and 100,000 × g to yield post-nuclear supernatant, P2, and P3, respectively. Pooled membrane fractions were further separated by density gradient centrifugation using step gradients consisting of 24, 19.33, 14.66, and 10% isotonic Nycodenz solutions (made in 0.75% NaCl, 10 mM Tris (pH 7.4), 3 mM KCl, and 1 mM EDTA) and were fractionated using a density gradient fractionator. The fractions were then analyzed by Western blotting using antibodies to PS2, sorcin, and other marker proteins.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Identification of Sorcin as an Interactor for the Large Hydrophilic Loop Region of PS2-- To search for putative interacting proteins for the PS2 loop region, we performed a domain-specific homology search of GenBankTM. The protein synexin was found to have a high degree of homology between its N terminus and a portion of the large hydrophilic loop region of PS2 (Fig. 1A). Synexin, also known as annexin VII, is a member of the annexin family of calcium- and phospholipid-binding proteins (50). We then asked whether the protein sorcin, which has previously been shown to interact with the N-terminal region of synexin (47), might also interact with the PS2 loop. Sorcin is a member of the family of Ca2+-binding proteins harboring five EF-hand motifs (40, 41). We first isolated full-length sorcin cDNA from an adult human brain library and subcloned it into an expression plasmid encoding the Myc epitope tag; Myc-tagged sorcin (Myc-sorcin) was then stably transfected into human neuroblastoma SY5Y cells (Fig. 1B). Western blot analysis using anti-Myc antibody revealed Myc-sorcin with an apparent molecular mass of 29 kDa, and anti-sorcin antibodies detected a ~29-kDa transgene-derived epitope-tagged form of sorcin as well as the 26-kDa endogenous sorcin (Fig. 1B). We next performed complementary co-immunoprecipitation analyses of PS2 and Myc-sorcin using alpha PS2Loop antibody (30) in lysates prepared from COS cells transfected with either Myc-sorcin or a Myc-tagged control protein, Myc-grancalcin, or Myc-XIAP (Fig. 1C). Only Myc-sorcin was co-immunoprecipitated by alpha PS2Loop, indicating that Myc-sorcin interacts with endogenous PS2 C-terminal (loop) fragments (PS2-CTF) (Fig. 1C).


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 1.   Identification of sorcin as an interactor for the large hydrophilic loop region of PS2. A, homology between the large hydrophilic loop domain region of PS2 and the N-terminal region of synexin. Amino acids 319-347 of human PS2 are compared with amino acids 17-56 of human synexin. Identical residues are indicated by straight lines and similar residues are indicated by a + between the sequences. B, expression and detection of sorcin in stable sorcin cell lines. Human neuroblastoma SH-SY5Y cells were stably transfected with either empty vector (vector) or a Myc-tagged sorcin expression construct (myc-sorcin). The cell lysates were analyzed by Western blot analyses using anti-Myc (left) or polyclonal anti-sorcin (right) antibodies. C, identification of the interaction between sorcin and PS2 using co-immunoprecipitation of Myc-tagged sorcin and the endogenous PS2 C-terminal fragment (PS2-CTF). Detergent lysates from COS cells that were transiently transfected with the constructs indicated in the upper panel were immunoprecipitated (IP) with alpha PS2loop and were analyzed by Western blotting using anti-Myc antibody. Myc-tagged sorcin that co-immunoprecipitates with endogenous PS2-CTF is indicated by an arrow. D, detection of sorcin in human neuroblastoma cells and brain using combined immunoprecipitation-Western blot analyses. Detergent lysates were prepared from cultured native SH-SY5Y cells (left) or human temporal cortex (right), and samples were subjected to immunoprecipitation with either pre-immune sera or polyclonal anti-sorcin antibodies and then analyzed by Western blotting with monoclonal anti-sorcin antibodies. E, co-immunoprecipitation of sorcin and PS2-CTF in human brain extracts. Temporal cortex tissues from neurologically normal patients were homogenized, lysed in the presence of 0.5% Nonidet P-40, and subjected to immunoprecipitation using alpha PS2Loop, with alpha PS1Loop used as a control antibody. Immunoprecipitates were then analyzed by Western blotting using polyclonal anti-sorcin antibody. Representative data from five independent experiments are shown.

Sorcin was detectable in human temporal cortex by combined immunoprecipitation-Western blotting analyses using two separate antibodies raised against human sorcin (Fig. 1D). Sorcin in the human temporal cortex (~28 kDa) exhibited a slightly larger apparent molecular mass than sorcin in SH-SY5Y cells (~26 kDa), possibly due to alternative splicing; a molecular mass of ~26-28 kDa is also slightly larger than the previously reported ~22 kDa (39, 40). To determine whether this endogenous sorcin associates with endogenous PS2 in vivo, detergent lysates were prepared from human temporal cortex and subjected to co-immunoprecipitation using alpha PS2Loop antibody or with alpha PS1Loop (30) as a negative control (Fig. 1E). Endogenous sorcin was recovered from these samples using only alpha PS2Loop (Fig. 1E), indicating that sorcin associates with PS2 but not with PS1 in the brain.

Subcellular Localization of the Sorcin-PS2 Molecular Complex-- To explore the cellular function of the PS2/sorcin interaction, we next attempted to determine the subcellular locus wherein the PS2/sorcin interaction occurs. For this purpose, we first visualized sorcin and PS2-CTF in stable PS2-expressing SH-SY5Y cell lines using double immunofluorescence confocal microscopy (Fig. 2A). PS2 immunoreactivity was mainly detected in smooth ER/Golgi-like intracellular membrane compartments, whereas sorcin immunoreactivity was more disperse (Fig. 2A). Sorcin and PS2-CTF co-localized only to a restricted subcellular region (Fig. 2A, yellow indicates overlapping signals). Since sorcin is a cytosolic protein (51) and PS2 is a known integral membrane protein (52), we predicted that a subset of cytosolic sorcin might associate with membranous subcellular structures to allow the interaction of sorcin with PS2. To locate the PS2-sorcin interaction, we performed subcellular fractionation using stable PS2 SH-SY5Y cell lines. After an initial homogenization and differential centrifugation, sorcin was predominantly found in the cytosolic fraction, although sorcin immunoreactivity was also detectable in the heavy membrane fraction, P2 (Fig. 2B). As predicted, PS2-CTF was absent in the cytosolic fraction and was highly enriched in the P2 fraction, where membrane-associated sorcin was detected (Fig. 2B).


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 2.   Subcellular localization of the sorcin-PS2 complex. A, immunofluorescence confocal microscopy of sorcin and PS2. Stable SY5Y cell lines expressing wild-type PS2 were fixed, permeabilized, and double-labeled with either monoclonal anti-sorcin antibody (red, Cy3) or alpha PS2loop (green, Bodipy). B, subcellular distribution of sorcin in cytosolic and membrane subcellular fractions. Wild-type PS2 stable SH-SY5Y cells were subjected to cell fractionation and differential centrifugation to yield post-nuclear supernatant (PNS), cytosol, and heavy (P2, 14,000 × g) and light (P3, 100,000 × g) membrane fractions. Equal amounts of protein from each subcellular fraction were analyzed by Western blotting using monoclonal anti-sorcin antibody or alpha PS2Loop. C, subcellular distribution of the sorcin-PS2 complex in density gradient subcellular fractions. Total membrane fractions from stable SY5Y cells expressing wild-type PS2 were separated on a discontinuous Nycodenz gradient. Fractions were collected from the top using a density gradient fractionator. Equal volumes of each fraction were analyzed by Western blotting using alpha PS2loop, monoclonal anti-sorcin antibody, anti-calcineurin B, and APS26 (anti-PS2 NTF, where NTF is N-terminal fragment) as well as antibodies to known subcellular organelle markers, including calnexin, GM130, and transferrin receptor (Tf-R). Representative data from three independent experiments are presented.

To define the specific subcellular membrane compartment where the PS2/sorcin interaction occurs, total membrane fractions prepared from SH-SY5Y stably cells expressing wild-type PS2 were further separated using Nycodenz discontinuous density gradient centrifugation (48, 49). Each fraction was analyzed by Western blotting using antibodies to PS2 and sorcin (Fig. 2C). The full-length PS2 polypeptide exhibited virtually identical subcellular distribution to that of calnexin, a rough ER marker (arrow a, Fig. 2C). In contrast, the PS2-CTF was visualized in three major peaks: peak one (fractions 3 and 4), peak two (fractions 6-8), and peak three (fractions 11 and 12) (Fig. 2C). Sorcin and PS2 were co-localized only to peak one membrane fractions, indicating that the PS2-sorcin complex was localized specifically to this subcellular compartment (arrow b, Fig. 2C). In addition, we performed Western blot analyses using antibodies to multiple subcellular marker proteins. Interestingly, 19-kDa calcineurin B, a Ca2+-binding subunit of calcineurin, was distinctively co-distributed with sorcin in the Nycodenz gradient fractions (Fig. 2C). Membrane-associated sorcin did not appear to co-localize with the majority of other subcellular markers tested, including alpha -adaptin, gamma -adaptin, clathrin light chain, BAG-1, and Bcl-2 (data not shown). Neither the Golgi matrix protein GM130 nor the transferrin receptor co-distributed with sorcin or PS2 (Fig. 2C). These data demonstrate that membrane-associated sorcin and a subset of PS2 endoproteolytic fragments, but not full-length PS2, co-localize together to a subcellular compartment that is positive for calcineurin B. Our data also indicate that the C-terminal endoproteolytic fragment and full-length forms of PS2 localize to different subcellular compartments in SH-SY5Y cells (Fig. 2C).

Sorcin Associates with the PS2 Endoproteolytic C-terminal Fragment but Not with Full-length PS2-- To determine further the PS2 species that predominantly interacts with sorcin, we co-immunoprecipitated PS2 using anti-sorcin antibodies (Fig. 3A). The levels of PS2-CTF that co-immunoprecipitated with endogenous sorcin were proportional to the levels of PS2-CTF detected in total cell lysates (data not shown). Virtually no full-length PS2 was recovered in the sorcin immunoprecipitates, confirming that sorcin preferentially interacts with PS2-CTF (Fig. 3A).


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 3.   Interaction of sorcin with the C-terminal endoproteolytic fragment but not with full-length PS2. A, co-immunoprecipitation (Co-IP) of the PS2 CTF with endogenous sorcin using anti-sorcin antibody in stable SH-SY5Y cells. Detergent lysates from stable SH-SY5Y cells expressing vector (lane 1) or wild-type PS2 (lane 2) were immunoprecipitated (IP) with monoclonal anti-sorcin antibodies. The PS2-CTF that co-immunoprecipitated with sorcin was detected by Western blotting using alpha PS2Loop (top panel) or sorcin antibodies (bottom panel). The predicted location of full-length PS2 is indicated by an arrow (FL). Other immunoreactivities in the gel derive from mouse IgG light and heavy chains (*). B, accumulation of the full-length and high molecular forms of PS2 induced by treatment with proteasome inhibitors fails to enhance the interaction between PS2 and sorcin. Stable SH-SY5Y cell lines expressing wild-type PS2 were incubated for 6 h with Me2SO (lanes 1, 4, and 7) or proteasome inhibitors ALLN (lanes 2, 5, and 8) or MG132 (lanes 3, 6, and 9). Detergent lysates were subjected to co-immunoprecipitation using alpha PS2loop. Immunoprecipitates along with straight cell lysates (20 µg each; lanes 7-9) were analyzed by Western blot analyses using the antibodies indicated in the bottom panels. The locations of full-length PS2 and the normal and alternative PS2 C-terminal fragments are indicated by arrows.

We next tested whether increased accumulation of full-length PS2 affects the interaction between sorcin and PS2. Both treatment with the proteasome inhibitors MG132 or ALLN (Fig. 3B) and overexpression of PS2 by transient transfection (data not shown) have previously been shown to lead to increased levels of full-length PS2 and ubiquitin-positive high molecular weight forms of PS2 but not PS2 endoproteolytic fragments (32, 53). No increase was observed in the interaction between PS2 and sorcin under either condition. Along with the subcellular fractionation data, our studies reveal that sorcin interacts with a subset of the PS2 complexes consisting of the endoproteolytic fragments but does not interact with full-length PS2.

Elevated Intracellular Calcium Enhances the Sorcin/PS2 Interaction and Translocation of Sorcin to the Membrane-- We next examined whether increasing the cytosolic Ca2+ concentration modulates the sorcin/PS2 interaction. Treatment with the Ca2+ ionophore A23187 did not alter the steady-state levels of sorcin or PS2 (Fig. 4A). Meanwhile, the level of sorcin that co-immunoprecipitated with alpha PS2Loop greatly increased as the result of A23187 treatment (Fig. 4A). To explore the possibility that Ca2+ mediates the translocation of the sorcin-PS2 complex, we examined the subcellular distribution of membrane-associated sorcin in PS2-expressing cells that were grown in the presence or absence of A23187. Although A23187 did not alter the subcellular distribution of the sorcin-PS2 complex, we found that A23187 treatment led to increased association of sorcin with the membrane (Fig. 4B). Our studies demonstrate that sorcin is translocated from the cytosol to the membrane when cytosolic Ca2+ is elevated by this ionophore, indicating that the recruitment of sorcin into a molecular complex harboring PS2 is modulated by intracellular Ca2+ levels.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 4.   Elevated intracellular calcium enhances the association of sorcin with PS2 and the recruitment of sorcin to the membrane. A, treatment with the calcium ionophore A23187 increases the binding between sorcin and PS2. SY5Y cells stably expressing wild-type PS2 were grown in the presence of Me2SO (lanes 1 and 3) or 20 µM A23187 for 3 h, and detergent lysates were subjected to co-immunoprecipitation using alpha PS2loop. The amount of sorcin that co-immunoprecipitated with PS2-CTF was greatly enhanced by treatment with A23187, whereas the total amount of sorcin in the lysates remained unchanged. B, A23187 treatment increases the association of sorcin with membrane fractions. Stable PS2 SY5Y cells were grown in the above-mentioned conditions and were subjected to subcellular fractionation as described in Fig. 2. Equal volumes of each fraction were analyzed by Western blot analyses using sorcin antibodies, and sorcin immunoreactivities were normalized to the unit membrane protein in the subcellular fractions and plotted.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

We report that presenilin 2 interacts endogenously with sorcin, a modulator of the RyR intracellular Ca2+-releasing channel. Regulation of ryanodine receptor activity by accessory molecules has been implicated in synaptic plasticity and other neuronal activities (43, 54-56). We have also shown that membrane-bound forms of sorcin co-fractionate with a subset of PS2 endoproteolytic fragments to a subcellular compartment harboring calcineurin B (Fig. 2C), another Ca2+-binding molecule that appears to be involved in the regulation of both inositol 1,4,5-trisphosphate- and ryanodine-sensitive intracellular Ca2+ channels (57). In addition, the PS2-sorcin interaction and the translocation of sorcin to the membrane appear to be increased by elevated intracellular Ca2+ levels (Fig. 4). These data reveal a molecular link between PS2 and cellular Ca2+ channels and raise the possibility that sorcin is recruited by PS2 into a molecular complex involved in intracellular Ca2+ modulation. In the future, it will be important to characterize the membranous organelles harboring the PS2-sorcin complex and to determine whether the PS2-sorcin complex includes an intracellular Ca2+ channel (e.g. RyR) as a primary component.

Although other Ca2+-binding proteins have been shown to interact with PS2, such as calsenilin and calmyrin (26, 27), these interactions were demonstrated only in cells transiently transfected with PS2 cDNAs (26, 27). We (Fig. 3 and Ref. 53) and others (30) have demonstrated that overexpression of PS2 leads to an accumulation of full-length PS2, whereas levels of PS2 fragments are reduced or unchanged. Accordingly, the PS2 species that were found to interact detectably with calsenilin and calmyrin were full-length PS2 but not PS2 endoproteolytic fragments (26, 27). Because growing evidence indicates that the endoproteolytic fragments comprise the functional units of the presenilins (11, 30), rather than the full-length proteins, calsenilin and calmyrin most likely play a role in the proteolysis, trafficking, or stabilization of full-length PS2 intermediates. In contrast, our data show that sorcin interacts with a subset of PS2 endoproteolytic fragments but not with full-length PS2, further supporting the possibility that the sorcin-PS2 interaction has a functional role (i.e. in Ca2+ modulation).

Implications of the sorcin-PS2 interaction for FAD remain to be elucidated. Since the large hydrophilic loop regions are divergent between PS1 and PS2 and no FAD mutation has been identified in the putative sorcin binding region of PS2 (synexin homologous domain), the exact contributions of sorcin and other PS1/PS2 loop-interacting molecules to AD neuropathogenesis have not been fully elucidated (16-19, 58). Interestingly, increased amyloid beta -peptide levels can result from RyR-driven elevations in intracellular Ca2+ (59). On the other hand, decreased RyR activity correlates with early pathological changes in AD (60). To this end, we are currently investigating whether the sorcin/PS2 interaction is involved in either Ca2+-related increases in amyloid beta -peptide or observed defects in RyR activity in AD. In any event, our study implies that the sorcin/PS2 interaction may play a normal and/or pathological role in intracellular Ca2+ homeostasis.

    ACKNOWLEDGEMENTS

We thank L. Kanaley-Andrews and E. Bird at the Harvard Brain Tissue Resources Center for postmortem brain tissues; M. Kim for helpful discussions; T. Z. Grenfell and A. J. Saunders for critical review of the manuscript; and G. Thinakaran, S. Sisodia, T. Tomita, T. Iwatsubo, A. Diehlmann, K. Beyreuther, and I. Trowbridge for antibodies.

    FOOTNOTES

* This work was supported in part by NIA grants from the National Institutes of Health and the Alzheimer's Association.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Kenner Fellow of the American Heart Association.

** Howard Hughes Medical Institute Medical Student Training Fellow.

Dagger Dagger Recipient of the Partners Investigator (Nesson) award. To whom correspondence should be addressed. Tel.: 617-726-3739; Fax: 617-726-5677; E-mail: kim@helix.mgh.harvard.edu.

Published, JBC Papers in Press, March 15, 2000, DOI 10.1074/jbc.M909882199

    ABBREVIATIONS

The abbreviations used are: FAD, familial Alzheimer's disease; AD, Alzheimer's disease; CTF, C-terminal fragment; PS1, presenilin 1; PS2, presenilin 2; RyR, ryanodine receptor.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Tanzi, R. E., Kovacs, D. M., Kim, T.-W., Moir, R. D., Guenette, S. Y., and Wasco, W. (1996) Neurobiol. Dis. 3, 159-168
2. De Strooper, B., Saftig, P., Craessaerts, K., Vandersticheles, H., Guhde, G., Annaert, W., Von Figura, K., and Van Leuven, F. (1998) Nature 391, 387-390
3. Steiner, H., Duff, K., Capell, A., Romig, H., Grim, M. G., Lincoln, S., Hardy, J., Yu, X., Picciano, M., Fechteler, K., Citron, M., Kopan, R., Pesold, B., Keck, S., Baader, M., Tomita, T., Iwatsubo, T., Baumeister, R., and Haass, C. (1999) J. Biol. Chem. 274, 28669-28673
4. Wolfe, M. S., Xia, W., Ostaszewski, B. L., Diehl, T. S., Kimberly, W. T., and Selkoe, D. J. (1999) Nature 398, 513-517
5. De Strooper, B., Annaert, W., Cupers, P., Saftig, P., Craessaerts, K., Mumm, J., Schroeter, E. H., Schrijvers, V., Wolfe, M. S., Ray, W. J., Goate, A., and Kopan, R. (1999) Nature 398, 518-222
6. Struhl, G., and Greenwald, I. (1999) Nature 398, 522-525
7. Ye, Y., Lukinova, N., and Fortini, M. E. (1999) Nature 398, 525-529
8. Naruse, S., Thinakaran, G., Luo, J.-J., Kusiak, J. W., Tomita, T., Iwatsubo, T., Qian, X., Ginty, D. D., Price, D. L., Borchelt, D. R., Wong, P. C., and Sisodia, S. S. (1998) Neuron 21, 1213-1221
9. Hardy, J. (1997) Trends Neurosci. 20, 154-159
10. Selkoe, D. J. (1998) Trends Cell Biol. 8, 447-453
11. Thinakaran, G. (1999) J. Clin. Invest. 104, 1321-1327
12. Guo, Q., Furukawa, K., Sopher, B. L., Pham, D. G., Xie, J., Robinson, N., Martin, G. M., and Mattson, M. P. (1996) Neuroreport 8, 379-383
13. Leissring, M. A., Parker, I., and LaFerla, F. M. (1999) J. Biol. Chem. 274, 32535-32538
14. Zhou, J., Liyanage, U., Medina, M., Ho, C., Simmons, A. D., Lovett, M., and Kosik, K. S. (1997) Neuroreport 8, 2085-2090
15. Tesco, G., Kim, T.-W., Diehlmann, A., Beyreuther, K., and Tanzi, R. E. (1998) J. Biol. Chem. 273, 33909-33914
16. Zhang, Z., Hartmann, H., Do, V. M., Abramowski, D., Sturchler-Pierrat, C., Staufenbiel, M., Sommer, B., van de Wetering, M., Clevers, H., Saftig, P., De Strooper, B., He, X., and Yankner, B. A. (1998) Nature 395, 698-702
17. Murayama, M., Tanaka, S., Palacino, J., Murayama, O., Honda, T., Sun, X., Yasutake, K., Nihonmatsu, N., Wolozin, B., and Takashima, A. (1998) FEBS Lett. 433, 73-77
18. Nishimura, M, Yu, G., Levesque, G., Zhang, D. M., Ruel, L., Chen, F., Milman, P., Holmes, E., Liang, Y., Kawarai, T., Jo, E., Supala, A., Rogaeva, E., Xu, D.-M., Janus, C., Levesque, L., Bi, Q., Duthie, M., Rozmahel, R., Mattila, K., Lannfelt, L., Westaway, D., Mount, H. T. J., Woodgett, J., Fraser, P. E., and St. George-Hyslop, P. (1999) Nat. Med. 5, 164-169
19. Kang, D. E., Soriano, S., Frosch, M. P., Collins, T., Naruse, S., Sisodia, S. S., Leibowitz, G., Levine, F., and Koo, E. H. (1999) J. Neurosci. 19, 4229-4237
20. Stahl, B., Diehlmann, A., and Südhof, T. C. (1999) J. Biol. Chem. 274, 9141-9148
21. Xia, W., Zhang, J., Perez, R., Koo, E. H., and Selkoe, D. J. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 8208-8213
22. Zhang, W., Han, S. W., McKeel, D. W., Goate, A., and Wu, J. Y. (1998) J. Neurosci. 18, 914-922
23. Ray, W. J., Yao, M., Nowotny, P., Mumm, J., Zhang, W., Wu, J. Y., Kopan, R., and Goate, A. M. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 3263-3268
24. Takashima, A., Murayama, M., Murayama, O., Kohno, T., Honda, T., Yasutake, K., Nihonmatsu, N., Mercken, M., Yamaguchi, H., Sugihara, S., and Wolozin, B. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 9637-9641
25. Dumanchin, C., Czech, C., Campion, D., Cuif, M. H., Poyot, T., Martin, C., Charbonnier, F., Goud, B., Pradier, L., and Frebourg, T. (1999) Hum. Mol. Genet. 8, 1263-1269
26. Buxbaum, J. D., Choi, E.-K., Luo, Y., Lilliehook, C., Crowley, A. C., Merriam, D. E., and Wasco, W. (1998) Nat. Med. 4, 1177-1181
27. Stabler, S. M., Ostrowski, L. L., Janicki, S. M., and Monteiro, M. J. (1999) J. Cell Biol. 145, 1277-1292
28. Imafuku, I., Masaki, T., Waragai, M., Takeuchi, S., Kawabata, M., Hirai, S.-I., Ohno, S., Nee, L. E., Lippa, C. F., Kanazawa, I., Imagawa, M., and Okazawa, H. (1999) J. Cell Biol. 147, 121-133
29. Passer, B. J., Pellegrini, L., Vito, P., Ganjei, J. K., and D'Adamio, L. (1999) J. Biol. Chem. 274, 24007-24013
30. Thinakaran, G., Borcehlt, D., Lee, M., Slunt, H., Spitzer, L., Kim, G., Ratovitsky, T., Davenport, F., Nordstedt, C., Seeger, M., Hardy, J., Levey, A. L., Gandy, S. E., Jenkinds, N. A., Copeland, N. G., Price, D., L., and Sisodia, S. S. (1996) Neuron 17, 181-190
31. Mercken, M., Takahashi, H., Honda, T., Sato, K., Murayama, M., Nakazato, Y., Noguchi, K., Imahori, K., and Takashima, A. (1996) FEBS Lett. 389, 297-303
32. Kim, T.-W., Pettingell, W. H., Hallmark, O. G., Moir, R. D., Wasco, W., and Tanzi, R. E. (1997) J. Biol. Chem. 272, 11006-11010
33. Seeger, M., Nordstedt, C., Petanceska, S., Kovacs, D. M., Gouras, G. K., Hahne, S., Fraser, P., Levesque, L., Czernik, A. J., St. George-Hyslop, P., Sisodia, S. S., Thinakaran, G., Tanzi, R. E., Greengard, P., and Gandy, P. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 5090-5094
34. Thinakaran, G., Regard, J. B., Bouton, C. M. L., Harris, C. L., Price, D. L., Borchelt, D. R., and Sisodia, S. S. (1998) Neurobiol. Dis. 4, 438-453
35. Capell, A., Grünberg, J., Pesold, B., Diehlmann, A., Citron, M., Nixon, R., Beyreuther, K., Selkoe, D. J., and Haass, C. (1998) J. Biol. Chem. 273, 3205-3211
36. Marambaud, P., Ancolio, K., Lopez-Perez, E., and Checler, F. (1998) Mol. Med. 4, 147-157
37. Honda, T., Yasutake, K., Nihonmatsu, N., Mercken, M., Takahashi, H., Murayama, O., Murayama, M., Sato, K., Omori, A., Tsubuki, S., Saido, T. C., and Takashima, A. (1999) J. Neurochem. 72, 255-261
38. Fraser, P. E., Levesque, G., Yu, G., Mills, L. R., Thirwell, J., Frantseva, M., Gandy, S. E., Seeger, M., Carlen, P. L., and St. George-Hyslop, P. (1998) Neurobiol. Aging 19, 19-21
39. Meyers, M. B., Pickel, V. M., Sheu, S.-S., Sharma, V. K., Scotto, K. W., and Fishman, G. I. (1995) J. Biol. Chem. 270, 26411-26418
40. Van der Bliek, A. M., Meyers, M. B., Biedler, J. L., Hes, E., and Borst, P. (1986) EMBO J. 5, 3201-3208
41. Maki, M., Narayama, S. V. L., and Hitomi, K. (1997) Biochem. J. 328, 718-720
42. Lokuta, A. J., Meyers, M. B., Sanders, P. R., Fishman, G. I., and Valdivia, H. H. (1997) J. Biol. Chem. 272, 25333-25338
43. Valdivia, H. H. (1998) Trends Pharmacol. Sci. 19, 479-482
44. Pickel, V. M., Clarke, C. L., and Meyers, M. B. (1997) J. Comp. Neurol. 386, 625-634
45. Boyhan, A., Casimir, C. M., French, J. K., Teahan, C. G., and Segal, A. W. (1992) J. Biol. Chem. 267, 2928-2933
46. Tomita, T., Maruyama, K., Saido, T. C., Kume, H., Shinozaki, K., Tokuhiro, S., Capell, A., Walter, J., Grünberg, J., Haass, C., Iwatsubo, T., and Obata, K. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 2025-2030
47. Brownawell, A. M., and Creutz, C. E. (1997) J. Biol. Chem. 272, 22182-22190
48. Hammond, C., and Helenius, A. (1994) J. Cell Biol. 126, 41-52
49. Kim, M., Velier, J., Chase, K., Laforet, G., Kalchman, M. A., Hayden, M. R., Won, L., Heller, A., Aronin, N., and DiFiglia, M. (1999) Neuroscience 89, 1159-1167
50. Creutz, C. E. (1992) Science 258, 924-931
51. Meyers, M. B., Zamparelli, C., Verzili, D., Dicker, A. P., Blanck, T. J., and Chiancone, E. (1995) FEBS Lett. 357, 230-234
52. Doan, A., Thinakaran, G., Borchelt, D. R., Slunt, H. H., Ratovitsky, T., Podlisny, M., Selkoe, D. J., Seeger, M., Gandy, S. E., Price, D. L., and Sisodia, S. S. (1996) Neuron 7, 1023-1030
53. Kim, T.-W., Pettingell, W. H., Jung, Y.-K., Kovacs, D. M., and Tanzi, R. E. (1997) Science 277, 373-376
54. Alkon, D. L., Nelson, T. J., Zhao, W., and Cavallaro, S. (1998) Trends Neurosci. 21, 529-537
55. Berridge, M. J. (1998) Neuron 21, 13-26
56. Balschun, D., Wolfer, D. P., Bertocchini, F., Barone, B., Conti, A., Zuschratter, W., Missiaen, L., Lipp, H.-P., Frey, J. U., and Sorrentino, V. (1999) EMBO J. 18, 5264-5273
57. Cameron, A. M., Steiner, J. P., Roskams, A. J., Ali, S. M., Ronnett, G. V., and Snyder, S. H. (1995) Cell 83, 463-472
58. Saura, C. A., Taisuke, T., Iwatsubo, T., and Thinakaran, G. (1999) Soc. Neurosci. Abstr. 25, 56
59. Querfurth, H. W., Jiang, J., Geiger, J. D., and Selkoe, D. J. (1997) J. Neurochem. 69, 1580-1591
60. Kelliher, M., Fastbom, J., Cowburn, R. F., Bonkale, W., Ohm, T. G., Ravid, R., Sorrentino, V., and O'Neill, C. (1999) Neuroscience 92, 499-513


Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
FASEB J.Home page
L. P. Collis, M. B. Meyers, J. Zhang, C. K. L. Phoon, E. A. Sobie, W. A. Coetzee, and G. I. Fishman
Expression of a sorcin missense mutation in the heart modulates excitation-contraction coupling
FASEB J, February 1, 2007; 21(2): 475 - 487.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. E. Kang, I. S. Yoon, E. Repetto, T. Busse, N. Yermian, L. Ie, and E. H. Koo
Presenilins Mediate Phosphatidylinositol 3-Kinase/AKT and ERK Activation via Select Signaling Receptors: SELECTIVITY OF PS2 IN PLATELET-DERIVED GROWTH FACTOR SIGNALING
J. Biol. Chem., September 9, 2005; 280(36): 31537 - 31547.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
A. Verkhratsky
Physiology and Pathophysiology of the Calcium Store in the Endoplasmic Reticulum of Neurons
Physiol Rev, January 1, 2005; 85(1): 201 - 279.
[Abstract] [Full Text] [PDF]


Home page
J BiochemHome page
H. Shibata, K. Yamada, T. Mizuno, C. Yorikawa, H. Takahashi, H. Satoh, Y. Kitaura, and M. Maki
The Penta-EF-Hand Protein ALG-2 Interacts with a Region Containing PxY Repeats in Alix/AIP1, Which Is Required for the Subcellular Punctate Distribution of the Amino-Terminal Truncation Form of Alix/AIP1
J. Biochem., January 1, 2004; 135(1): 117 - 128.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. B. Meyers, A. Fischer, Y.-J. Sun, C. M. B. Lopes, T. Rohacs, T. Y. Nakamura, Y.-Y. Zhou, P. C. Lee, R. A. Altschuld, S. A. McCune, et al.
Sorcin Regulates Excitation-Contraction Coupling in the Heart
J. Biol. Chem., August 1, 2003; 278(31): 28865 - 28871.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Mella, G. Colotti, C. Zamparelli, D. Verzili, A. Ilari, and E. Chiancone
Information Transfer in the Penta-EF-hand Protein Sorcin Does Not Operate via the Canonical Structural/Functional Pairing: A STUDY WITH SITE-SPECIFIC MUTANTS
J. Biol. Chem., June 27, 2003; 278(27): 24921 - 24928.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
E. L. Meyer, N. Strutz, L. C. Gahring, and S. W. Rogers
Glutamate Receptor Subunit 3 Is Modified by Site-specific Limited Proteolysis Including Cleavage by {gamma}-Secretase
J. Biol. Chem., June 20, 2003; 278(26): 23786 - 23796.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
N. Kitagawa, S. Shimohama, T. Oeda, K. Uemura, R. Kohno, A. Kuzuya, H. Shibasaki, and N. Ishii
The Role of the Presenilin-1 Homologue Gene sel-12 of Caenorhabditis elegans in Apoptotic Activities
J. Biol. Chem., March 28, 2003; 278(14): 12130 - 12134.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Morohashi, N. Hatano, S. Ohya, R. Takikawa, T. Watabiki, N. Takasugi, Y. Imaizumi, T. Tomita, and T. Iwatsubo
Molecular Cloning and Characterization of CALP/KChIP4, a Novel EF-hand Protein Interacting with Presenilin 2 and Voltage-gated Potassium Channel Subunit Kv4
J. Biol. Chem., April 19, 2002; 277(17): 14965 - 14975.
[Abstract] [Full Text] [PDF]


Home page
Protein Sci.Home page
X. Xie, M. D. Dwyer, L. Swenson, M. H. Parker, and M. C. Botfield
Crystal structure of calcium-free human sorcin: A member of the penta-EF-hand protein family
Protein Sci., December 1, 2001; 10(12): 2419 - 2425.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
H. Tanahashi and T. Tabira
Alzheimer's disease-associated presenilin 2 interacts with DRAL, an LIM-domain protein
Hum. Mol. Genet., September 1, 2000; 9(15): 2281 - 2289.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
E.-K. Choi, N. F. Zaidi, J. S. Miller, A. C. Crowley, D. E. Merriam, C. Lilliehook, J. D. Buxbaum, and W. Wasco
Calsenilin Is a Substrate for Caspase-3 That Preferentially Interacts with the Familial Alzheimer's Disease-associated C-terminal Fragment of Presenilin 2
J. Biol. Chem., May 25, 2001; 276(22): 19197 - 19204.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H.-J. Lee, K.-M. Jung, Y. Z. Huang, L. B. Bennett, J. S. Lee, L. Mei, and T.-W. Kim
Presenilin-dependent gamma -Secretase-like Intramembrane Cleavage of ErbB4
J. Biol. Chem., February 15, 2002; 277(8): 6318 - 6323.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
275/19/14440    most recent
M909882199v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pack-Chung, E.
Right arrow Articles by Kim, T.-W.
Right arrow Search for Related Content